– USA, MA – Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the election of Bo Cumbo to its board of directors. Mr. Cumbo is a veteran of the biotechnology industry and has played strategically important roles in the successful launch of 11 products across multiple organizations and therapeutic categories, including rare neuromuscular diseases, hepatitis, HIV, and cardiovascular disease.
“In his more than twenty-year career in the biotechnology and pharmaceutical sectors, Bo has played an integral role in the planning and implementation of numerous, highly successful and industry-leading commercial product launches,” said Doug Treco, PhD, President and Chief Executive Officer of Ra Pharma. “With this deep expertise and global commercial leadership experience, we are thrilled to welcome Bo to our board and welcome the valuable insights he will bring.”
About Bo Cumbo
Mr. Cumbo serves as Senior Vice President and Chief Commercial Officer of Cambridge, Massachusetts-based Sarepta Therapeutics, Inc. (Nasdaq:SRPT), a leader in precision genetic medicine for rare diseases. Mr. Cumbo joined Sarepta in 2013, leading and establishing the Company’s commercial function as Sarepta developed into a global commercial organization. During his tenure with Sarepta, Mr. Cumbo has been responsible for directing one of the most successful ultra-rare product launches in history for EXONDYS 51™ (eteplirsen). From 2010 to 2013, Mr. Cumbo served as Vice President of Sales and Treatment Education for Vertex Pharmaceuticals, launching Incivek, a treatment for hepatitis C. Prior to Vertex, Mr. Cumbo served in multiple commercial roles supporting the HIV, HBV, and cardiovascular franchises at Gilead Sciences. Mr. Cumbo has extensive experience building pre- and post-global commercial infrastructure, and throughout his career, he has contributed to the launch of 11 specialty products across multiple organizations. Mr. Cumbo received his Bachelor of Science in Medical Technology from Auburn University.
“Ra Pharma has the potential to transform treatment paradigms across multiple complement-mediated disorders,” said Mr. Cumbo. “This potential begins with zilucoplan, a subcutaneously self-administered complement inhibitor that, if approved, could disrupt standards of care by affording patients greater accessibility, flexibility, and convenience. I look forward to working with this dynamic and talented team at this critical juncture in the Company’s life cycle.”
About Ra Pharmaceuticals
Ra Pharmaceuticals is a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for complement-mediated diseases. The Company discovers and develops peptides and small molecules to target key components of the complement cascade.
For more, visit: www.rapharma.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
